Please login to the form below

Not currently logged in
Email:
Password:

Ophthotech

This page shows the latest Ophthotech news and features for those working in and with pharma, biotech and healthcare.

Novartis' AMD drug pegpleranib fails phase III programme

Novartis' AMD drug pegpleranib fails phase III programme

The results of two phase III trials of pegpleranib - an anti-PDGF aptamer originally developed by OphthoTech - showed that adding it to therapy with Lucentis (ranibizumab) in patients with the neovascular ... While a minor blow to Novartis as well as

Latest news

  • Novartis licenses Ophthotech eye drug in $1bn deal Novartis licenses Ophthotech eye drug in $1bn deal

    s Avastin (bevacizumab), so the Ophthotech deal gives Novartis an alternative therapeutic option as well as the possibility of developing a combination treatment. ... Ophthotech has retained rights to the drug in the US and will also earn royalties on

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Acquisition of voucher. 125. AVEO Oncology / Ophthotech Corporation. VEGF tyrosine kinase inhibitor tivozanib.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    1, 400. Ophthotech / Novartis. Commercialisation. 1. and co-development licence. Fovista (start p3) for treatment of wet age-related macular degeneration.

  • Pharma deals during May 2014 Pharma deals during May 2014

    Top of the list was Ophthotech's commercialisation and co-development agreement with Novartis for Fovista, an anti-PDGF agent, in phase 3 for wet age-related macular degeneration (AMD).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics